
CURRICULUM VITAE



September 11, 2015

DEMOGRAPHIC INFORMATION

Current Appointments

2015-current	Vice-President of Therapeutics Development, Cystic Fibrosis Foundation
2015-current	Adjunct Professor of Medicine, Johns Hopkins University School of Medicine

Personal Data

The Cystic Fibrosis Foundation 6931 Arlington Road, Suite 200 Bethesda, MD 20814



The Johns Hopkins Division of Pulmonary and Critical Care Medicine 1830 East Monument Street, 5th floor Baltimore, MD 21287



Hospital Address:

The Johns Hopkins Hospital 1800 Orleans Street Baltimore, MD 21287

Education and Training

Undergraduate

1982-1986: B.S. (Biochemistry and Honors Program), University of Maryland

Doctoral/graduate

1986 to 1991: M.D. Johns Hopkins University School of Medicine

Post-doctoral

1990-1991:	Dean's Research Year, Johns Hopkins School of Medicine
1991-1992:	Intern, Internal Medicine, Johns Hopkins Hospital
1992-1994:	Resident, Internal Medicine, Johns Hopkins Hospital
1996-1999:	Fellow, Pulmonary and Critical Care Medicine, Johns Hopkins Hospital
1997	Johns Hopkins School of Public Health Summer Institute: Conduct of Clinical Trials
2004-2005:	Johns Hopkins School of Public Health: Biostatistics I-III

Professional Experience

1994-1996	Faculty, Greater Baltimore Medical Center, Department of Medicine
1999-2002	Instructor of Medicine, Johns Hopkins University School of Medicine
2002-2006	Assistant Professor of Medicine, Johns Hopkins University School of Medicine
2006-2014	Associate Professor of Medicine, Johns Hopkins University School of Medicine
2014-2015	Professor of Medicine, Johns Hopkins University School of Medicine
2015-current	Adjunct Professor of Medicine

RESEARCH ACTIVITY: (H-index 33)

Peer-reviewed Original Science Publications

- 1. Weisman HF, Bartow T, Leppo MK, Marsh HC, Carson GR, Concino MF, **Boyle MP**, Roux KH, Weisfeldt ML, Fearon DT. Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and Necrosis. *Science* 249:146-151, 1990.
- Weisman HF, Bartow T, Leppo MK, Boyle MP, Marsh HC, Carson GR, Roux KH, Weisfeldt ML, Fearon DT. Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium. *Trans Assoc Am Physicians* 103:64-72, 1990.
- 3. **Boyle MP**, Weisman HF. Limitation of Infarct Expansion and Ventricular Remodeling by Late Reperfusion: Study of Time Course and Mechanism in a Rat Model. *Circulation* 88:2872-2883, 1993.
- 4. Zeitlin PL, Rubenstein RC, **Boyle MP**, Chu SC. Phenylbutyrate Therapy for Cystic Fibrosis: Basic Mechanisms and Clinical Applications. *Pediatric Pulmonology* 26:164-166, 1998.
- 5. Boyle MP. Minocycline Induced Pancreatitis in Cystic Fibrosis. Chest 119:1283-1285, 2001.
- 6. **Boyle MP**, Enke RA, Adams RJ, Guggino WB, Zeitlin PL. *In-Utero* AAV-Mediated Gene Transfer to Rabbit Pulmonary Epithelium. *Molecular Therapy* 4: 115-121, 2001.
- Noone PG, Hamblett N, Accurso F, Aitken ML, Boyle MP, Dovey M, Gibson R, Johnson C, Kellerman D, Konstan MW, Milgram L, Mundahl J, Retsch-Bogort G, Rodman D, Williams-Warren J, Wilmott RW, Zeitlin P, Ramsey B. Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: Results of a phase I multi-center study. *Pediatric Pulmonology* 32: 122-8, 2001.
- 8. **Boyle MP**, Farukhi Z, Nosky ML. Strategies for Improving Transition to Adult Cystic Fibrosis Care Based on Patient and Parent Views. *Pediatric Pulmonology* 32:428-436, 2001.
- 9. Zeitlin PL, Diener-West M, Rubenstein R, **Boyle MP**, Lee C, Brass-Ernst L. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. *Molecular Therapy* 6: 119-126, 2002.
- 10. **Boyle MP**, Enke RA, Mogayzel PJ, Guggino WB, Martin DB, Agarwal S, Zeitlin PL. Effect of Adeno-associated virus-specific Immunoglobulin G in Human Amniotic Fluid on Gene Transfer. *Human Gene Therapy* 14:365-373, 2003.
- Boyle MP, Diener-West M, Milgram LJ, Knowles MR, Foy C, Zeitlin PL, Standaert TA and the CFTDN Nasal PD Study Group. A Multi-Center Study of the Effect of Solution Temperature on Nasal Potential Difference Measurements. *Chest* 124:482-489, 2003.
- 12. Merlo CA, Boyle MP. Modifier Genes in Cystic Fibrosis Lung Disease. J Lab Clin Med 141: 237-241, 2003.
- 13. Zeitlin PL, **Boyle MP**, Guggino WB, Molina L. A Phase I Trial of Moli1901 for Cystic Fibrosis. *Chest* 125:143-149, 2004.
- 14. Aris RM, Merkel PA, Bachrach LK, Borowitz DS, **Boyle MP**, Elkin SL, Guise TA, Hardin DS, Haworth CS, Holick MF, Joseph PM, O'Brien K, Tullis E, Watts NB, White TB. Guide to Bone Health and Disease in Cystic Fibrosis. *J Clin Endocrinol Metab 9*0:1888-1896, 2005.
- 15. **Boyle MP**, Noschese ML, Watts SL, Davis ME, Stenner S, Lechtzin N. Failure of High-Dose Ergocalciferol to Correct Vitamin D Deficiency in Adults with Cystic Fibrosis. *Am J Respir Crit Care Med* 172:212-7, 2005.
- 16. Lechtzin N, Manju J, Irizarry R, Merlo C, Diette GB, **Boyle MP**. Outcomes of Adults with Cystic Fibrosis Infected With Multiple Antibiotic Resistant Pseudomonas Aeruginosa. *Respiration* 73:27-33, 2006.
- 17. **Boyle MP**, Enke RA, Reynolds JB, Mogayzel PJ, Guggino WB, and Zeitlin PL. Membrane-associated heparin sulfate is not required for rAAV-2 infection of human respiratory epithelia. *Virology J* 3:29, 2006.
- Wright JL, Merlo CA, Reynolds JB, Zeitlin PL, Garcia JGN, Guggino WB, Boyle MP. Microarray Analysis of Human Nasal Respiratory Epithelial Cells from Cystic Fibrosis ΔF508 Homozygotes with Mild and Severe Lung Disease Am J Respir Crit Mol Bio 35:327-36, 2006. PMID: 16614352.
- 19. Lee CKK, **Boyle MP**, Diener-West M, Brass-Ernst L, Noschese M, Zeitlin PL. Levofloxacin Pharmacokinetics in Adult Cystic Fibrosis. *Chest* 131: 796-802, 2007.
- 20. Boyle MP. Strategies for Identifying Novel Modifier Genes in Cystic Fibrosis. *Proceedings of American Thoracic Society*, 4:52-57, 2007. PMID: 17202292.

- Buranawuti K, Boyle MP, Cheng S, McDougal K, Fallin MD, Merlo C, Zeitlin PL, Rosenstein BJ, Mogayzel PJ, Wang X, Cutting GR. Variants in Mannose-Binding Lectin and Tumor Necrosis Factor Affect Survival in Cystic Fibrosis. *Journal of Human Genetics* 44:209-214, 2007. PMID: 17158822.
- 22. Riekert KA, Bartlett SJ, **Boyle MP**, Krishnan JA, Rand CS. The Association between Depression, Lung Function and Health Related Quality of Life among Adults with Cystic Fibrosis. *Chest* 132:231-237, 2007.
- 23. Hsu SC, Groman J, Merlo C, Naughton K, Zeitlin P, Germain-Lee E, **Boyle MP** and Cutting GR. Mutations in Gsα cause reduced activation of downstream targets in epithelial tissues due to haplo-insufficiency. *J Clin Endocrinol Metab* 92:3941-8, 2007. PMID: 17652219.
- 24. Merlo CA, **Boyle MP**, Diener-West M, Marshall B, Goss CH, Lechtzin N. Incidence and Risk Factors for Multiple Antibiotic Resistant Pseudomonas aeruginosa in Cystic Fibrosis. *Chest* 132:562-568, 2007.
- 25. **Boyle MP**, Singh C, Sabadosa K, Haase J, Hollon K, Lester MK, Quinton H. The Adult CF Benchmarking Project: What Have We Learned? *Pediatric Pulmonology* 30:165-167, 2007.
- 26. McLaughlin SE, Diener-West M, Indurkhya A, Rubin H, Heckmann R, **Boyle MP**. Improving Transition from Pediatric to Adult Cystic Fibrosis Care: Lessons from a National Survey of Current Practices. *Pediatrics*. 1212:1160-1166, 2008.
- 27. Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, **Boyle MP**. Persistent Methicillin-resistant Staphylococcus Aureus and Rate of FEV1 Decline in Cystic Fibrosis. *Am J Respir Crit Care Med* 178:814-821; 2008. PMID: 18669817.
- 28. Suk JS, Lai SK, Wang Y-Y, Ensign LM, Zeitlin PL, **Boyle MP**, Hanes J, The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles, *Biomaterials* 30:2591–2597, 2009.
- 29. Tang BC, Dawson M, Lai SK, Wang Y, Suk JS, Yang M, Zeitlin P, **Boyle MP**, Fu J, Hanes J. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier, *Proc Natl Acad Sci USA* 106:19268-73, 2009.
- 30. Sudfeld CR, Dasenbrook EC, Merz WG, Carroll KC, **Boyle MP**. Prevalence and Risk Factors for Recovery of Filamentous Fungi in Individuals with Cystic Fibrosis. *Journal of Cystic Fibrosis*. 9:110-6, 2010. PMID: 20045384.
- Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. Association of Respiratory Tract Methicillin-Resistant Staphylococcus Aureus and Survival in Cystic Fibrosis. JAMA 303:2386-92, 2010. PMID: 20551409
- 32. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Flume PA, Mogayzel PJ Jr, Robinson KA, Rosenblatt RL, Quittell L, Marshall BC; Clinical Practice Guidelines for Pulmonary Therapies Committee; Cystic Fibrosis Foundation Pulmonary Therapies Committee. *Am J Respir Crit Care Med.* 182:298-306, 2010. PMID: 20675678.
- 33. Modi AC, Quittner AL, **Boyle MP**. Disclosure of Chronic Disease in Adults with Cystic Fibrosis: the Adult Data for Understanding Lifestyle and Transitions (ADULT) Survey. *BMC Pulmonary* 10:46, 2010. PMID: 20831811.
- 34. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz J, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, Freedman SD, Dong Q, Zha J, Stone AJ, Olson ER, Ordonez CL, Campbell PW, Ashlock MA, Ramsey BW. VX-770, a Novel CFTR Potentiator in Cystic Fibrosis Patients with the G551D Mutation. NEJM 363:1991-2003, 2010. PMID: 21083385.
- 35. Suk JS, Lai SK, Boylan NJ, Dawson MR, **Boyle MP**, Hanes J. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetylcysteine. *Nanomedicine*. 6:365-75, 2011. PMID: 21385138.
- Eakin MN, Bilderback MS, Boyle MP, Mogayzel PJ, Riekert KA. Longitudinal Association between Medication Adherence and Lung Function among People with Cystic Fibrosis. *Journal of Cystic Fibrosis*. 10:258-64, 2011. PMID:21458391
- 37. West NE, Lechtzin N, Merlo CA, Turowski JB, Davis ME, Ramsay MZ, Watts SL, Stenner SP, **Boyle MP**. Appropriate goal level for 25-hydroxyvitamin D in cystic fibrosis. *Chest.* 140:469-74, 2011. PMID: 21393390.
- 38. Hida K, Lai SK, Suk JS, Won SY, **Boyle MP**, Hanes J. Common gene therapy viral vectors do not efficiently penetrate sputum from cystic fibrosis patients. *PLoS One*. 2011;6(5):e19919. PMID: 21637751.
- Boylan NJ, Suk JS, Lai SK, Jelinek R, Boyle MP, Cooper MJ, Hanes J. Highly compacted DNA nanoparticles with low MW PEG coatings: In vitro, ex vivo and in vivo evaluation. *J Control Release*. 2012 Jan 10;157(1):72-9. Epub 2011 Aug 31. PubMed PMID: 21903145
- Suk JS, Boylan NJ, Trehan K, Tang BC, Schneider CS, Lin JM, Boyle MP, Zeitlin PL, Lai SK, Cooper MJ, Hanes J. N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles. *Mol Ther.* 19:1981-9, 2011. PPMID: 21829177
- 41. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Campbell PW, Bronsveld I, DeBoeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Lebecque P, McCoy KS, Moss RB, Pilewski JM, Rosenbluth D, Rubenstein RC, Schechter MS, Botfield M, Cui Y, Ordoñez CL, Spencer-Green GT, Vernillet L, Wisseh S, Yen K, Konstan MW. Results of a Phase 2a study of VX-809, an investigational CFTR corrector compound, in cystic fibrosis subjects homozygous for the F508del-CFTR mutation. *Thorax* 67:12-18, 2012. PMID: 21825083

- 42. Lechtzin N, West N, Allgood S, Wilhelmz E, Khan U, Mayer-Hamblett N, Aitken ML, Ramsey BW, **Boyle MP**, Mogayzel PJ Jr, Goss CH. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: The early intervention in cystic fibrosis exacerbation (eICE) trial. *Contemp Clin Trials.* 36:460-469, 2013 PMID: 24055998.
- 43. Rowe SM, Liu B, Hill A, Hathorne H, Cohen M, Beamer JR, Accurso FJ, Dong Q, Ordoñez CL, Stone AJ, Olson ER, Clancy JP; VX06-770-101 Study Group. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation. *PLoS One.* 26;8(7):e66955, 2013 PMID:23922647
- 44. Suk JS, Kim AJ, Trehan K, Schneider CS, Cebotaru L, Woodward OM, Boylan NJ, **Boyle MP**, Lai SK, Guggino WB, Hanes J. Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier. *J Control Release*. 2014 Jan 14; 178C: 8-17 PMID: 24440664.
- 45. **Boyle MP**, Sabadosa KA, Quinton HB, Marshall BC, Schechter MS. Key Findings of the Cystic Fibrosis Foundation's U.S. Clinical Practice Benchmarking Project. *BMJ Quality and Safety*. 23:i15-i22, 2014. PMID: 24608546.
- 46. Jennings MT, **Boyle MP**, Weaver D, Callahan K, Dasenbrook EC. Eradication Strategy for Persistent Methicillin-Resistant Staphylococcus aureus Infection in Individuals with Cystic Fibrosis: Rationale and Design of the PMEP Randomized Clinical Trial. *Trials* 15:223, 2014. PMID: 24925006.
- 47. Hanes J, Schuster B, Kim A, Kays J, Kanzawa M, Guggino W, **Boyle MP**, Rowe S, Muzyczka N, and Suk JS. Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectors. *Molecular Therapy*. 22:1484-93, 2014. PMID: 24869933.
- 48. Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR, Rodman D. on behalf of the VX09-809-102 Study Group. Randomised Trial of Combined CFTR Corrector and Potentiator Therapy in F508del-*CFTR* Cystic Fibrosis. *The Lancet Respiratory Medicine*. 2: 527-38, 2014. PMID: 24973281.
- 49. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015 Jul 16;373(3):220-31.
- Mastorakos P, da Silva AL, Chisholm J, Song E, Choi WK, Boyle MP, Morales MM, Hanes J, Suk JS. Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy. Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8720-5. doi: 10.1073/pnas.1502281112. Epub 2015 Jun 29. PMID: 26124127.

Invited Reviews

- 1. **Boyle MP**. Unique Presentations and Chronic Complications in Adult Cystic Fibrosis: Do they teach us anything about CFTR? *Respiratory Research* 1:125-128, 2000.
- 2. Boyle MP. The Spectrum of CFTR-related disease. Internal Medicine 40(7): 522-525, 2001.
- 3. Boyle MP. Nonclassic Cystic Fibrosis and CFTR-related diseases. Current Opinions in Pulmonary Med. 9:498-503, 2003.
- 4. Boyle MP. So many drugs, so little time the future challenge of cystic fibrosis care? Chest 123: 3-5, 2003.
- 5. Boyle MP. Update on Maintaining Bone Health in Cystic Fibrosis. Current Opinions in Pulmonary Med, 12:453-8. 2006.
- 6. Boyle MP. Adult Cystic Fibrosis: Medical Grand Rounds. JAMA 298:1787-93, 2007.
- 7. Boyle MP. Cystic Fibrosis: Year in Review. Current Opinion in Pulmonary Medicine 16:583, 2010. PMID: 20829695.
- 8. Rowe S, Boyle MP. Combination of Correctors & Potentiators for F508del CFTR. Ped Pulmonol. S34: 180-181, 2011.
- 9. **Boyle MP**, Jennings M, Dasenbrook ED. Clinical Trial Designs for Methicillin-Resistant Staph Aureus (MRSA) in CF. *Pediatric Pulmonology* S34: 141-143, 2011.
- 10. **Boyle MP** and De Boeck K. A New Era in Cystic Fibrosis Therapeutics: Correcting the Underlying CFTR Defect. *The Lancet Respiratory Medicine* 1:158-163, 2013.
- 11. Jennings MT, Riekert KA, and **Boyle MP**. *Medical Principles and Practice*. Update on Key Emerging Challenges in Cystic Fibrosis, 2014 Jan 10. [Epub ahead of print] PubMed PMID: 24434297.

Consensus Conference Statements

- 1. Cystic Fibrosis Adult Care Consensus Conference Report. Cystic Fibrosis Foundation Concepts in CF Care, Volume IX, Section 3, July 1999.
- 2. Guide to Bone Health and Disease in Cystic Fibrosis Consensus Conference Report. Cystic Fibrosis Foundation Concepts in CF Care, Volume X, Section 4, June 2002.

Inventions, Patents, Copyrights

2012 Investigational New Drug (IND) from FDA – IND # 114966 Awarded April 16, 2012 IND Holder: Michael Boyle, M.D.

Extramural Sponsorship

1/1/03 - 12/31/15	Annual CF Foundation Therapeutics Development Site Grant Cystic Fibrosis Foundation \$1,345,000
	Co-PI: 3%; Provides funding for Johns Hopkins CF Foundation Therapeutic Development Network Site
1/1/12 - 12/31/15	Randomized Multi-Center Clinical Trial of Treatment of MRSA in Cystic Fibrosis PMEP (Persistent MRSA Eradication Protocol) Cystic Fibrosis Foundation \$412,979 Role: PI, 15%
Previous	
7/99 - 6/01	Cystic Fibrosis Gene Therapy Bauernschmidt Fellowship \$70,000 Role: PI, 75%
4/00 - 3/04	AAV-mediated in-utero gene therapy Shwachman Award: BOYLE00Q0 Cystic Fibrosis Foundation \$245,000 Role: PI, 70%
9/00 - 9/04	Applied Genomics in Cardiopulmonary Disease (Clinical) U01 HL66618 NIH/NHLBI \$4,316,377 PI: Haponik, E/Garcia JGN Role: Co-Investigator, 5%; Dr. Boyle was the director of the Cystic Fibrosis component of this program, one of the three clinical diseases featured in the grant.
9/00 - 9/04	Applied Genomics in Cardiopulmonary Disease (Genotyping) U01 HL 66615 NIH/NHLBI \$3,177,914 PI: A.F. Scott Role: Co-Investigator, 5%; Dr. Boyle was a member of the genotyping and bioinformatics committees. This support was relinquished at the start of the K23 award.
9/01- 8/06	Twin and sibling study of heritable CF phenotypes R01 HL68927 NIH/NHLBI \$615,811 PI: Cutting, G Role: Co-Investigator/Clinical Phenotyping Coordinator, No salary support
7/02 - 6/04	Treatment of Osteopenia in CF Adults with Zoledronic Acid

	Cystic Fibrosis Foundation Clinical Research Award \$214,452 Role: PI; 7%
7/02 - 6/04	CF Foundation Research Development Program Grant CF Foundation \$2,000,000 PI: Guggino WB Role: Co-Investigator, 10%; Boyle - Career Development Award; This grant provides lab funding for investigating the molecular basis of difference in CF phenotype
7/03 - 10/08	Genetic modifiers of cystic fibrosis K23 HL071847 NIH/NHLBI \$657,450 Role: PI, 70%
7/07 - 7/08	The National Adult Cystic Fibrosis Benchmarking Project CF Foundation \$22, 103 Role: PI, 10%; This grant supports Dr. Boyle as leader of the Cystic Fibrosis Foundation's National Adult CF Quality Improvement and Benchmarking Effort.
7/07 - 6/09	A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of VX-770 to Evaluate Safety, Pharmacokinetics, and Biomarkers of CFTR Activity in Cystic Fibrosis (CF) Subjects with Genotype G551D (VX06-770-101); Phase 2a study of VX-770 VX06-770-101 Vertex Pharmaceuticals \$112,510 Role: PI, 4%
8/1/08 - 7/31/10	Molecular Phenotyping for Cystic Fibrosis Lung Disease R01 (Subcontract 5-51359) NIH/NHLBI \$99,858 PI: Knowles, Role: Co-Investigator, 10%; This grant will support the collection and analysis of respiratory epithelium from CF patients with particularly mild and severe lung disease.
9/08 - 8/09	A Phase I/II Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected with Pseudomonas aeruginosa. KaloBios Clinical Trials Contract KaloBios Pharmaceuticals \$51,378 Role: PI, 4%
5/1/09 - 4/30/10	A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of VX-809 to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of VX-809 in Cystic Fibrosis Subjects Homozygous for the DF508-CFTR Gene Mutation; VX-809 Study VX08-809-101 Vertex Pharmaceuticals \$132,281 Role: PI, 6%
8/1/09 - 7/31/11	A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of VX-770 to Evaluate Efficacy and Safety of VX-770 in Cystic Fibrosis Subjects with the G551D CFTR Gene Mutation; VX-770 Study VX08-770-102

	Vertex Pharmaceuticals \$163,324 Role: PI, 15%
12/1/09 - 11/30/10	Identifying & Implementing Key Practices to Improve National Adult CF Outcomes BOYLE09QI0 Cystic Fibrosis Foundation \$54,000 Role: PI, 20%; Supported the conduct of a National Adult CF Quality Improvement Initiative
8/1/10 -07/31/12	An Open Label Study of VX-770 to Evaluate Efficacy and Safety of VX-770 in Cystic Fibrosis Subjects with the G551D CFTR Gene Mutation, VX-770 Study VX08-770-105 Vertex Pharmaceuticals \$123,000 Role: PI, 5%
9/20/08 - 7/31/14	A Phase II Study of Digitoxin in Individuals with Cystic Fibrosis R01FD003456 US FDA \$750,000 PI: Zeitlin, P Role: Co-investigator, 5%
7/1/10 - 12/30/14	A Phase 3, randomized, Double-Blind, Placebo-Controlled Study of ivacaftor in subjects 6 years of age and older with Cystic Fibrosis and a R117H CFTR mutation; Phase III Study VX-770-110 Vertex Pharmaceuticals \$127,000; Role: PI, 5%;
12/1/10 - 11/30/14	A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of VX-809 to evaluate safety, pharmacokinetics, and pharmacodynamics of VX-809 in Cystic Fibrosis subjects homozygous for the DF508-CFTR gene mutation Multi-dose Study of VX-809 VX08-809-102 Vertex Pharmaceuticals \$342,281, Role: PI, 10%
1/1/13 - 12/31/14	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to evaluate the efficacy and safety of lumacaftor and Ivacaftor in subjects with Cystic Fibrosis who have the F508del CFTR mutation; Study of VX-809 VX08-809-103 Vertex Pharmaceuticals \$198,000 Role: PI, 10%
7/1/12 - 3/30/15	A Phase 3, two-arm, rollover study to evaluate the safety of long-term Ivacaftor treatment in subjects 6 years of age and older with Cystic Fibrosis and a R117H CFTR mutation, Phase III VX-770-112 Vertex Pharmaceuticals \$123,000 Role: PI, 5%
11/1/13 - 3/30/15	A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR mutation; Study of VX-809

	VX08-809-105 Vertex Pharmaceuticals \$434,681 Role: PI, 15%
1/1/14 - 3/30/15	Therapeutic Development Network Grant, Chairman Award Cystic Fibrosis Foundation \$175,810 Role: PI, 30%

Research Program Building/Leadership

2000-2015	U	Co-Director: Johns Hopkins Site, National Cystic Fibrosis Therapeutic Development Network
2001-2004		Member, Cystic Fibrosis Foundation Therapeutic Development Network Publications Committee
2003-2015		Member, Cystic Fibrosis Foundation Therapeutic Development Network Steering Committee [2003-
		2006, 2010-2015]
2004-2010		Member, Cystic Fibrosis Foundation Therapeutic Development Network Protocol Review Committee
2012-2013		Vice-Chairman, Cystic Fibrosis Foundation Therapeutic Development Network Steering Committee
2013-2015		Chairman, Cystic Fibrosis Foundation Therapeutic Development Network Steering Committee

EDUCATIONAL ACTIVITIES

Educational Publications

Case Reports

- 1. Boyle MP. Advanced Studies in Medicine, Vol 9, (1). Case Study: A Young Man with "Mild" Cystic Fibrosis, 2009.
- 2. Dezube R, Terry P, Akulian J, Mathai SC, **Boyle M**, Khasab T, Yarmus L. Chronic expanding hematoma of the lung. Am J Respir Crit Care Med. 188:e71, 2013.

Book Chapters

1. Merlo CA, **Boyle MP**. Adult Cystic Fibrosis. In *The Osler Handbook of Inpatient Medicine*. Mosby Inc. Philadelphia, PA. 2003.

Letters, Correspondence

- 1. Boyle MP, Orens JB. Distal Intestinal Obstruction Syndrome after Surgery in Cystic Fibrosis. Chest 124:2408-9, 2003.
- 2. Lechtzin N, Merlo CA, Boyle MP. Author's Reply. Respiration. 74:357, 2007.
- 3. Boyle MP. Joint Problems and Cystic Fibrosis-Reply. JAMA 299:408, 2008.

Other Media

- 1. **Boyle MP**. "Aerosolized Antibiotics: Case Studies in Optimizing Outcomes and Managing Compliance," CME CD-ROM, Program Director, *Johns Hopkins University School of Medicine Continuing Education*, August 2000.
- 2. Boyle MP. "Aerosolized Antibiotics in Lung Transplantation: Case Studies" CME CD-ROM, Program Director, *Johns Hopkins University School of Medicine Continuing Education*, May 2002.
- 3. Merlo CA, **Boyle MP**. "Cystic Fibrosis." On Johns Hopkins Genomics Program website at <u>www.Hopkins-genomics.org</u>, 2002.
- 4. Boyle MP. "Pregnancy and CF;" Article on MyCysticFibrosis.com website, 2005.
- 5. Boyle MP. "Highlights from NACFC 2005." Article on MyCysticFibrosis.com website, 2005.
- 6. Boyle MP. "Considering Having Children?" Article on MyCysticFibrosis.com website, 2005.
- 7. Boyle MP. "The Changing Face of Cystic Fibrosis." Newsweek's Weekly National Radio Show. Sept 4, 2005.
- 8. **Boyle MP.** "Thinking about having Children?" Educational Booklet Published by the Cystic Fibrosis Foundation, Bethesda, MD. 2006
- 9. **Boyle MP.** "Transition from Pediatric to Adult Care: It's a Transition for Parents As Well!" Article on MyCysticFibrosis.com website, 2007.
- 10. Boyle MP, Dasenbrook E. Emerging Pathogens in Cystic Fibrosis. eCysticFibrosis Review Vol 1:4, Nov 2008.
- 11. **Boyle MP**, Clancy JP, Riekert K. Optimizing Patient Outcomes: Clinical Use of the Cystic Fibrosis Pulmonary Guidelines. Johns Hopkins Advanced Studies in Medicine, 2009.

Other Media (Internet Educational Programs)

2008-2015 Program Director and Editor, eLiterature Review – bimonthly Cystic Fibrosis Literature re-	view.
http://www.hopkinscme.net/ofp/eCysticFibrosisReview/newsletters.html	
2009 Ahead of the Curve: Emerging CF Therapies 2009.	
http://www.hopkinscme.edu/ofp/eCysticFibrosisReview/nacfc/index.html	
2010 Ahead of the Curve: Cystic Fibrosis Genetics Revolution.	
http://www.hopkinsamd.org/AOTC_eCFS/index.html	
2010 Ahead of the Curve: CF Summit. <u>http://aotc-cf.reg.meeting-stream.com/1202enduring/</u>	
2011 Ahead of the Curve: Genetics Revolution for the CF Care Team.	
https://dkb.edmeasures.com/modules/dkb/index.html.php	
2012 The Pulmonary Personalized Medicine Challenge. <u>http://pulmonarychallenge.org/</u>	
2012 Ahead of the Curve: Inside CFTR – 3D Educational Experience. <u>http://aotc-insidecftr.or</u>	<u>s/</u>

Teaching

Classroom instruction

1999-2006	Small group leader, Pulmonary Anatomy Discussion Groups, Johns Hopkins School of Medicine
1999-2008	Small group leader, Pulmonary Pathophysiology Discussion Groups, Johns Hopkins School of Medicine
2011-present	Lecturer, Genes to Society Medical School Course, Cystic Fibrosis Section
Clinical instruc	tion
1994-1996	Clinical Skills: Instructor, Johns Hopkins School of Medicine
1999-present	Adult Cystic Fibrosis: Epidemiology, Diagnosis and Management," Ongoing monthly presentation to
	Osler housestaff rotating on pulmonary floor.
1999-present	Instructor, Medicine Residents CASE rotation - Adult Cystic Fibrosis Clinic
1999-present 2002-present	Instructor, Pulmonary Fellow Clinic Rotation - Adult Cystic Fibrosis Clinic Instructor, University of Maryland School of Genetic Counseling

CME instruction

7/21-25/07:	Course Director, Johns Hopkins Update in Pulmonary and Critical Care Medicine, Williamsburg, VA,
2008	Course Director: "Optimizing Patient Outcomes: Clinical Use of the Cystic Fibrosis Pulmonary
	Guidelines," Johns Hopkins Advanced Studies in Medicine.
8/1-5/08:	Course Director, Johns Hopkins Update in Pulmonary and Critical Care Medicine, Washington, DC,
8/1-5/09:	Course Director, Johns Hopkins Update in Pulmonary and Critical Care Medicine, Bar Harbor, ME,

Mentoring

Advisees

2000	Zareen Farukhi, M.D. Medical Student Research: "Strategies for Improving Transition to Adult Cystic
2000 2002	Fibrosis Care. "Currently Pediatrician, University of Washington
2000-2003	Raymond Enke, M.S. Research Assistant. Research Topic: Gene Therapy. Currently Ph.D Faculty
	Member at University of Virginia.
2001-2005	Christian Merlo, M.D. Pulmonary Fellowship Research Training: Outcomes of CF patients with Resistant
	Pseudomonas. Bauernschmidt Research Award Winner, Shwachman Award Winner. Currently Assistant
	Professor of Medicine, Johns Hopkins Division of Pulmonary and Critical Care Medicine. Recognized
	by ACCP as top 25 young investigator, 2005.
2002-2005	Kristin Riekert, PhD. (Co-sponsor of NRSA: "Adherence Behaviors in Adults with Cystic Fibrosis" as
	fellow, Currently Associate Professor of Medicine, Pulmonary and Critical Care Medicine, Johns Hopkins
2002-2004	Suzanne McClaughlin, M.D. Robert Wood Johnson Fellowship Awardee: "Transition of Care from
	Pediatric to Adult CF Care," Received MPH. Currently Assistant Professor of Pediatrics, Boston
	University School of Medicine.
2003	Uzelia Louis-Jacque, Minority College Student Program. Currently Internist, Baltimore, MD.
2005	Vasthie Prudent, Minority College Student Program. Currently MD PhD Student at NYU.
2006-2009	Elliott Dasenbrook, M.D., M.H.S. Pulmonary Fellowship Research Training: Awarded CF Foundation
	Fellowship Training Grant 2007-2009. Awarded CF Shwachman Award 2011-2014. Currently Associate
	Professor, Case Western University School of Medicine.
	9

- 2008-2012 Natalie West, M.D., M.H.S. Pulmonary Fellowship Research Training: Co-sponsor NRSA Award. Awarded CF Shwachman Award 2013-2015. Currently Assistant Professor, Johns Hopkins University School of Medicine.
 2011-present Mark Jennings, M.D. Pulmonary Fellowship Research Training: Awarded CF Foundation Fellowship
- Training Grant 2012-2013., National Research Service Award (NRSA) 2012-2014.
- 2014-present Rebecca Dezube, M.D. Pulmonary Fellowship Research Training. National Research Service Award (NRSA) 2015-2017.

Thesis Committees

- 2009 Jung Soo Suk, Ph.D. Johns Hopkins School of Engineering. "The penetration of fresh, undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles", Dissertation Committee Member.
- 2010 Lindsay Henderson, Ph.D. Johns Hopkins Genetics Program. "Genetic modifiers of cystic fibrosis pulmonary and intestinal phenotypes", Dissertation Committee Member.

Training Grant Participation

 7/1/99 - 6/30/18 Multidisciplinary Training Program in Lung Diseases. NIH/NHLBI T32 HL 07534, \$6,431,304 PI: Robert A. Wise, MD Role: Member of Advisory Council, Director of Participant Recruiting

Educational Program Building/Leadership

2002-2004	Chairman, CF Foundation National Patient and Family Education Committee
2004-2010	Member, Department of Medicine Intern Selection Committee
2005-2015	Director of Education, Johns Hopkins Division of Pulmonary & Critical Care Medicine.
2005-2011	Director, Pulmonary and Critical Care Fellowship Recruiting
2010-2013	Director, Carol Johns Service Medical Resident Pulmonary Rotation

Educational Extramural Funding None

CLINICAL ACTIVITIES

Certification

Medical, state 1994 -Present: Medical License, State of Maryland (D46141)

Boards, specialty certification

1994 - 2004: Certified, American Board of Internal Medicine (154820)

1999 - Present: Certified, Specialty Board of Pulmonary Medicine (154820)

Clinical Service Responsibilities

- 1999-2015 Staff the over 800 outpatient Adult CF visits and 120 inpatient admissions annually by conducting two weekly clinics and rounding on inpatients. Also manage three full-time cystic fibrosis clinical nurses and a social worker. In addition attend three months per year on pulmonary consultation and lung transplantation services.
- 2015 Attend in Adult Cystic Fibrosis Clinic Weekly, Mentor CF Clinical Team in Weekly Meetings. Cover the Johns Hopkins general pulmonary and critical care service 4 weekends per year.

Clinical Program Building/Leadership

- 1999 -2015: Director, Johns Hopkins Adult Cystic Fibrosis Program. Established, developed and now direct the Johns Hopkins Adult CF Program, one of the largest and best-known programs in the United States.
- 2010 -2013: Director, Carol Johns Pulmonary Service

Clinical Extramural Funding

7/1/05-3/30/15	C052: Adult CF Clinical Center Grant Cystic Fibrosis Foundation \$1,140,000 Co-PIs: Boyle MP, Mogayzel PJ; This grant supports the clinical activity of the Johns Hopkins Adult and Pediatric Cystic Fibrosis Programs
12/1/10 - 11/30/15	Improving Adult Cystic Fibrosis Social Work Support and Training at the Johns Hopkins Adult Cystic Fibrosis Program BOYLEBEF1 Boomer Esiason Foundation: \$358,057 Role: PI, no salary support; This grant pays for a full time social worker to aid in the clinical care of adults with Cystic Fibrosis cared for at the Johns Hopkins Adult CF Program

SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES

System Innovation and Quality Improvement Publications

- Boyle MP, Singh C, Sabadosa K, Haase J, Hollon K, Lester MK, Quinton H. The Adult CF Benchmarking Project: What Have We Learned? *Pediatric Pulmonology* 30:165-167, 2007.
- 2. **Boyle MP**. "Using the Tools We Have Now to Improve Cystic Fibrosis Outcomes", North American CF Conference Plenary Address, 2007, <u>http://www.cff.org/research/NACFC/2007NACFC/</u>.
- Boyle MP, Sabadosa KA, Quinton HB, Marshall BC, Schechter MS. Key Findings of the Cystic Fibrosis Foundation's U.S. Clinical Practice Benchmarking Project. *BMJ Quality and Safety*. 23:i15-i22, 2014. PMID: 24608546.

System Innovation and Quality Improvement within JHMI:

- 2006-2009 Member, Nelson 4 Safety and Quality Improvement Team
- 2012 Co-chair, Environment Focus Group, Division of Pulmonary and Critical Care Medicine

System Innovation and Quality Improvement/ Leadership outside of JHMI:

- 2006-2008 **Chairman,** Cystic Fibrosis Foundation National Adult Cystic Fibrosis Benchmarking Project. Identified, visited and assessed clinical practice patterns in the top ten performing Cystic Fibrosis Clinical Care Centers Nationwide
- 2008-2010 Member, American Thoracic Society Task Force on Quality Improvement

System Innovation and Quality Improvement Extramural Funding:

7/1/07 - 6/30/08	The National Adult Cystic Fibrosis Benchmarking Project CF Foundation Grant BOYLE07QI0 \$22,103 Role: PI, 10%; This grant supported Dr. Boyle as leader of the Cystic Fibrosis Foundation's National Adult CF Quality Improvement and Benchmarking Effort.
12/1/09-11/30/10	Identifying & Implementing Key Practices to Improve National Adult CF Outcomes Cystic Fibrosis Foundation BOYLE09QI0 \$54,000

Role: PI, 10%; This grant supported the conduct of a National Adult CF Quality Improvement Initiative

ORGANIZATIONAL ACTIVITIES

Institutional Administrative Appointments

2002 - 2005	Johns Hopkins Pulmonary Division Clinical Practices Working Group
2002 - 2005	Johns Hopkins Pulmonary Division Committee for Academic Faculty Career Development; Leader:
	Gender and Diversity Sub-group.
2005 - present	Director of Education, Pulmonary and Critical Care Medicine
2004 - 2010	Department of Medicine Intern Selection Committee
2005 - 2011	Director, Pulmonary and Critical Care Fellowship Recruitment
2010 - 2013	Director, Carol Johns Service Medical Resident Pulmonary Rotation

Editorial Activities

Editorial Board appointments

2003-2009	Member, CF Foundation Therapeutic Development Network Publications Committee
2008-2011	Editor, Current Opinions in Pulmonary Medicine – Cystic Fibrosis Section.
2008 to present	Editor, eCysticFibrosis Review Newsletter. Bimonthly Cystic Fibrosis Literature Review

Journal Reviewer

2003-present	Chest
2005-present	American Journal of Respiratory and Critical Care Medicine
2006-present	Proceedings of American Thoracic Society
2006-present	Molecular Therapy
2009	Expert Opinion in Pharmacotherapy
2009	BMC Genetics
2009	BMC Medicine
2010	Journal of Medical Case Reports
2011	BMC Pulmonary Medicine
2011	International Journal of Endocrinology
2012	Journal of Translational Medicine

Advisory Committees/ Review Groups/Study Sections

1999:	Member, Cystic Fibrosis Foundation Consensus Committee on Care of Adults with Cystic Fibrosis
2002 - 2003	Member, Cystic Fibrosis Foundation Consensus Committee on Bone Health in Cystic Fibrosis
2002 - 2004	Chairman, Cystic Fibrosis Foundation National Committee on Patient and Family Education. Was the inaugural chairman of this committee created by the CF Foundation to review and develop nationally standardized CF educational material
2002 - 2005	Member, Cystic Fibrosis Therapeutic Development Network Publications Committee
2003 - 2006	Member, Steering Committee, Cystic Fibrosis Therapeutic Development National Network. 60 center
	network responsible for performance of national CF phase I-III trials.
2004	FDA ad how Study Section for Review of Orphan Drug Grant Applications
2004 - present	Abstract Reviewer, Annual North American Cystic Fibrosis Conference
2004 - present	Ad hoc Reviewer, Cystic Fibrosis Foundation Therapeutics Grant Review
2005	FDA Ad-Hoc Study Section for Review of Orphan Drug Grant Applications
2005 - 2010	Member, Cystic Fibrosis Foundation's Therapeutic Development Network Protocol Review Committee
2006	National Osteoporosis Society – Grant Reviews
2006 - 2008	Chairman, Cystic Fibrosis Foundation National Adult Benchmarking Project. Led national multi- disciplinary team in identifying and visiting the ten Adult CF Programs with the best clinical outcomes
	with the goal of determining practice patterns that result in best Adult CF outcomes.
2007	Physician Advisor, Social Security Administration, National Hearings on Establishing Guidelines for
	Disability in Cystic Fibrosis
2008 - 2010	Member, American Thoracic Society Task Force on Quality Improvement
2009	Member, Cystic Fibrosis Foundation Expert Panel for Developing Treatment Guidelines for Hemoptysis and Pneumothorax in Cystic Fibrosis.

2009	Italian Cystic Fibrosis Foundation - Grant Review.
2009 - present	Member, North American Cystic Fibrosis Foundation Conference Planning Committee
2010	NIH (NIDDK) Study Section - Review of R24 Applications PAR-08-0181 - "Seeding Collaborative
	Interdisciplinary Team Science in Diabetes, Endocrinology and Metabolic Diseases"
2010 - 2015	Member, Steering Committee, Cystic Fibrosis Therapeutic Development National Network. 60 center
	network responsible for performance of national CF phase I-III trials.
2012	German Federal Research Ministry, Deutsche Forschungsgemeinschaft, Study Section - Review of Cystic
	Fibrosis Grant Submissions.
2012 - 2013	Vice-Chairman, Steering Committee, Cystic Fibrosis Therapeutic Development National Network. 74
	center network responsible for performance of national CF phase I-III trials.
2012 - 2014	Member, Joint CFF-European CF Society Consensus Care Committee on clinical care guidelines for
	assessment and treatment of Mental Health Issues in CF
2013 - 2015	Chairman, Steering Committee, Cystic Fibrosis Therapeutic Development National Network. 74 center
	network responsible for performance of national CF phase I-III trials.

Professional Societies

1994 - 1999	American College of Physicians
1999 - 2006	Maryland Thoracic Society: Member
1999 - present	American Thoracic Society: Member

1999 - present American College of Chest Physicians: Member

Member, Board of Directors

2002 - 2012: Cystic Fibrosis Services, Inc. (Subsidiary of the Cystic Fibrosis Foundation)

Conference Organizer, Session Chair

10/02	Chairman, Clinical Consultation Session, 2002 North American CF Meetings, New Orleans, LA
10/03	Chairman, Complicated Management Issues in CF Consultation Clinic, 2003 North American Cystic
	Fibrosis Meetings, Anaheim, CA
10/04	Chairman, Genetic Modifiers Session, 2004 North American Cystic Fibrosis Meetings, St. Louis, MO
10/04	Faculty, "Building an Adult Cystic Fibrosis Program," Educational Program, 2004 North American
	Cystic Fibrosis Meetings, St. Louis, MO
10/05	Chairman, Endocrine and Bone Disease Session, 2005 North American Cystic Fibrosis Meetings,
	Baltimore, MD
10/05	Faculty, "What the Adult Physician Needs to Know about CF" Educational Program, 2005 North
	American Cystic Fibrosis Meetings
5/06	Faculty, "Advances in the Understanding and Treatment of Cystic Fibrosis in Adults," 2006 American
	Thoracic Society Conference
10/06	Leader, Morning Breakfast Session, "Strategies for Maintaining Bone Health," 2006 North American
	Cystic Fibrosis Meetings
11/06	Chairman, Endocrine and Bone Disease Session, 2006 North American CF Meetings, Denver CO
10/07	Chairman, Quality Improvement in CF Symposium, 2007 North American Cystic Fibrosis Meetings,
	Anaheim, CA
10/08	Honorary Chairman, 2008 North American Cystic Fibrosis Meetings, Orlando, FL
10/08	Chairman, Adult Pulmonary Fellow Case Session, 2007 North American CF Meetings, Orlando, FL
10/09	Chairman, Adult Pulmonary Fellow Case Session, North American CF Meetings, Minneapolis, MN
10/09	Program Planning Committee, 2009 North American Cystic Fibrosis Meetings, Minneapolis, MN
10/10	Chairman, Adult Pulmonary Fellow Case Session, North American CF Meetings, Baltimore, MD
10/10	Program Planning Committee, 2010 North American Cystic Fibrosis Meetings, Baltimore, MD
10/11	Chairman, Adult Pulmonary Fellow Case Session, North American CF Meetings, Anaheim, CA
11/11	Program Planning Committee, 2011 North American Cystic Fibrosis Meetings, Anaheim, CA
5/12	Symposium Chairman, 2012 American Thoracic Society Meetings, "Adult Cystic Fibrosis: The
	Essentials," San Francisco, CA
5/12	Poster Session Chairman, 2012 American Thoracic Society Meetings, "New Therapies in Cystic Fibrosis,"
	San Francisco, CA
6/12	Chairman, Emerging Therapies Symposium, 2012 European Cystic Fibrosis Meetings, Dublin, Ireland
10/12	Symposium Chairman, Hot CF Issues: Pro/Con Debates. North American CF Meetings, Orlando, FL
10/12	Chairman, Adult Pulmonary Fellow Case Session, 2012 North American CF Meetings, Orlando, FL

6/13 Symposium Chairman, 2013 European Cystic Fibrosis Meetings, "The Organization of the CF Unit," Lisbon, Portugal 10/13Program Planning Committee, 2013 North American Cystic Fibrosis Meetings, Salt Lake City, UT. Program Planning Committee, 2014 North American Cystic Fibrosis Meetings, Atlanta, GA. 10/145/15Poster Session Moderator, Advances in CF, 2015 American Thoracic Society Meetings, Denver, CO Consultantships

2004-2009	MyCysticFibrosis.com
2005-2006	Corus Pharma, Inc. (Inhaled Aztreonam Development)
2009-2012	Novartis Inc. (Inhaled Dry Powder Tobramycin Development)
2010-2012	Pharmaxis Pharmaceuticals (Inhaled Mannitol Development)
2010-2013	Vertex (CFTR modulation therapy)
2011-2013	Savara Pharmaceuticals (Inhaled Vancomycin Development).

RECOGNITION

Awards and Honors

- 1982 National Merit Scholarship, University of Maryland
- Chancellor's Scholarship, University of Maryland 1982
- 1982 Honors Program Scholarship, University of Maryland
- Dean's Research Award. Johns Hopkins School of Medicine 1990
- 1991 Harold Lamport Award for Best Medical Student Biomedical Research, Johns Hopkins School of Medicine
- 1991 American Federation for Clinical Research Award
- 1996 Resident Teaching Appreciation Award, Greater Baltimore Medical Center
- 1999 Bauernschmidt Research Award, Johns Hopkins School of Medicine
- 2000 Shwachman Research Award, Cystic Fibrosis Foundation
- 2006 Alpha Omega Alpha (AOA), Johns Hopkins School of Medicine Chapter
- 2008 "Best Doctors in America" Selection (and again annually since then)
- 2008 George Comstock Career Achievement Award - American Lung Association
- 2008 Chairman, North American Cystic Fibrosis Conference
- Patients' Choice Award 2012
- 2012 Compassionate Doctor Award
- 2012 Kit Taylor Memorial Lecture, University of Rochester
- 2012 Osler Medicine House staff Teaching Award for Best Full-Time Faculty Teacher
- 2013 Fellows Teaching Award, Johns Hopkins Pulmonary and Critical Care Medicine, New York

Invited Talks

International

mematona	
6/08 Invited Speaker: "The National U.S. Adult Cystic Fibrosis Qua	lity Improvement/Benchmarking Project,"
2008 European Cystic Fibrosis Meetings, Prague, Czech Repub	olic
9/08 Plenary Speaker: "The Results of the National U.S. Adult Cysti	c Fibrosis Quality Improvement /
Benchmarking Project", 2008 United Kingdom Cystic Fibrosis	Trust Meetings, Manchester, England
11/08 Plenary Speaker: "Designing Your Cystic Fibrosis Care Program	n to Result in Best Patient Outcomes:
Why and How," 2008 German Cystic Fibrosis Society Annual	National Meeting (Deutsche
Mukoviszidose-Tagung), Wurzburg, Germany	
1/09 Keynote Speaker: 40th Anniversary Celebration of the Netherla	nds Cystic Fibrosis Society. "Delivering
the Best CF Care by Learning from Your Own and Other Cen	ters," Amsterdam, Netherlands
9/09 Speaker, "Preparing Your Child with CF to Transition to Adult	t CF Care," 2009 Australian CF Parents
and Family Conference, Brisbane, Australia	
10/09 Featured Plenary Speaker: "Lessons Learned for the U.S. Natio	onal CF Benchmarking Study," 2009
Biannual Australasian Cystic Fibrosis Meeting, Brisbane, Austra	alia
8/10 Guest Faculty, "Adult CF Care and Lung Transplantation". Cy	ystic Fibrosis Foundation Live Webcast -
one hour broadcast internationally	
12/11 Conference Speaker: "Resistant Organisms in Cystic Fibrosis,"	2011 Israeli Cystic Fibrosis Meetings, Ein
Gedi, Israel.	
12/11 Conference Speaker: "Taking Care of Adults with Cystic Fibro	sis," 2011 Israeli CF Meetings, Ein Gedi,
Israel.	


- 12/11 Family Day Speaker: "Preparing Your Teen with CF to be a Successful Adult with CF" Hadassah Hospital Family Day, Jerusalem, Israel.
- 2/11 Symposium Speaker: "Use of the National CF Registry to Improve CF Clinical Care," Irish Cystic Fibrosis Meetings, Killarney, Ireland
- 6/11 Symposium Speaker: "Using Benchmarking to Encourage Continuous Quality Improvement at Cystic Fibrosis Centers," European CF Center Quality Improvement Symposium, 2011 European Cystic Fibrosis Society Meetings, Hamburg, Germany
- 6/12 Symposium Speaker: "Emerging Therapies Addressing CFTR Dysfunction," 2012 European Cystic Fibrosis Meetings. Dublin, Ireland
- 1/13 International Webcast Faculty Presentation: "Results from the Vertex VX-809-102 Trial," 2013 CF Unite Educational Day, London, UK
- Boyle M, Bell S, Konstan M, McColley S, Flume P, Kang L, Wu Y, Waltz D, Patel N for the VX09-809-102 Study Group. Lumacaftor, an investigational CFTR corrector, in combination with Ivacaftor, a CFTR potentiator, in CF patients with the F508Del-CFTR mutation. Journal of Cystic Fibrosis 12;S1:S14. (Presented by Michael Boyle at European CF Meetings 2013)
- 6/13 Symposium Speaker: "Correcting and Potentiating CFTR," 2013 European Cystic Fibrosis Meetings. Lisbon, Portugal
- 6/13 Symposium Speaker: "Quality Control: The Role of Peer Review," 2013 European Cystic Fibrosis Meetings. Lisbon, Portugal
- 6/14 "Update on CFTR Correctors", European CF Conference Symposium Lecture, Gothenburg, Sweden

National

6/99	"Current Demographics of Adult Cystic Fibrosis" Presentation to Cystic Fibrosis Foundation Consensus
	Committee on Care of the Adult Cystic Fibrosis Patient, Washington, DC
3/00	"Caring for Adults with Cystic Fibrosis: A New Challenge for the New Millennium," Maryland Thoracic
	Society Address, Baltimore, MD
4/00	"Transitioning and Caring for the Adult Cystic Fibrosis Patient," Washington D.C. Symposium: Cystic
	Fibrosis in the Next Millennium
5/01	"Genomics and Cystic Fibrosis:" NIH Program for Genomic Applications (PGA) Lecture Series
11/01	"Evidence Based Approach to Treatment of COPD," VHA Southeast Pneumonia and COPD Forum,
	Orlando, FL
1/02	"Adult Cystic Fibrosis Clinical Research Update," New York State Thoracic Society Address, West Point,
	NY
3/03	"Pregnancy and Cystic Fibrosis," Children's National Medical Center Pulmonary Division Grand Rounds,
	Washington DC
4/03	"Update in Cystic Fibrosis Clinical Care and Research," NYU/ Bellevue Hospital Pulmonary Grand
	Rounds, New York, NY
12/03	"Genetics of Cystic Fibrosis: What have we learned since discovery of the gene?" A.I Dupont Hospital
	for Children Grand Rounds
3/04	"Adult Cystic Fibrosis," National Naval Medical Center Medical Grand Rounds, Washington, DC
4/04	"Meet the Professor: Practical Steps to Implementing Infection Control Measures at a Cystic Fibrosis
	Center." Society for Hospital Epidemiologists of America National Meeting
11/04	"Incorporating Clinical Research into an Adult CF Program" North American Cystic Fibrosis Meetings,
5/05	"Update in Cystic Fibrosis Clinical Care and Research," Mt. Sinai Medical Center Pulmonary and Critical
	Care Grand Rounds, New York, NY
7/05	Understanding the Basis of Variability in Severity of CF Lung Disease," Stanford University Division of
	Pulmonary and Critical Care Medicine Lectureship, Palo Alto, CA
10/05	"Correlation of Serum Vitamin 25-OHD Levels and PTH levels in CF," North American Cystic Fibrosis
	Meetings
10/05	"Cystic Fibrosis, TIVADs, and Hypercoagulability," Physician Grand Rounds, North American Cystic
	Fibrosis Meetings
10/05	"Cystic Fibrosis and Bone Health," North American Cystic Fibrosis Meetings
10/05	"Implementing Infection Control Measures at a Cystic Fibrosis Center." North American Cystic Fibrosis
	Meetings
11/05	"Making the Adult with CF Part of their own Care Team," North American Cystic Fibrosis Meetings
2/06	Update in Cystic Fibrosis," Pinnacle Health Annual Pulmonary Symposium

3/06	"When to Suspect and How to Diagnose Mild Cases of Cystic Fibrosis," Maryland Thoracic Society Annual Scientific Session, Baltimore, MD
4/06	"CFTR Expression in CF Airway Epithelium: RNA and Protein Detection," Cystic Fibrosis Foundation Therapeutic Development Network Annual Meetings, Seattle, WA
4/06	"The Johns Hopkins Adult CF Program Quality Improvement Initiative", Learning and Leadership Collaborative IV, Cystic Fibrosis Foundation, Bethesda, MD
5/06	"Genotype and Phenotype Relationships in Cystic Fibrosis and How It Helps Us Recognize Mild Forms
F /07	of Cystic Fibrosis," American Thoracic Society Address, San Diego, CA
5/06	"Genotype/Phenotype Relationships and the Diagnosis of Atypical CF in Adults," American Thoracic Society International Conference
6/06	"Effect of Resistant Pseudomonas on Clinical Outcomes in CF," Cystic Fibrosis Foundation Annual Williamsburg Cystic Fibrosis Research Conference
6/06	"Multiple Antibiotic Resistant Pseudomonas Aeruginosa Infection: Risk Factors and Effect on CF
	Outcomes," Cystic Fibrosis Foundation's Annual National Williamsburg Scientific Meetings,
	Williamsburg, VA
10/07	Plenary Address: "Improving Outcomes Using the Tools that We Have Now," North American Cystic
4.0.407	Fibrosis Meetings, http://www.cff.org/research/NACFC/2007NACFC/
10/07	"The National Adult Benchmarking Initiative: What Have We Learned?" North American Cystic
4/09	Fibrosis Meetings What is the effect of Mathiellin Resistant Stank Aurous on Custin Fibrosis Lung Disease? Columbia
4/08	What is the effect of Methicillin Resistant Staph Aureus on Cystic Fibrosis Lung Disease? Columbia University Adult Cystic Fibrosis National Symposium, New York, NY
4/09	"Cystic Fibrosis as a Model of Specialty Center Care," National Ataxia-Telangiectasia Meetings,
1,00	Baltimore, MD
5/09	"Results of the National Adult CF Benchmarking Project," Annual Randall Rupracht Lecture, University
	of California, San Francisco, San Francisco, CA
10/09	"Effect of VX-770 on Spirometry and Quality of Life," 2009 North American Cystic Fibrosis Meetings,
	2009 North American CF Meetings, Orlando, FL
11/09	"What's New in Cystic Fibrosis?" Wake Forest University Medical Center Pulmonary Grand Rounds,
10/00	Winston-Salem, NC
12/09	"Top 5 New Developments in Cystic Fibrosis," Albany Medical Center Grand Rounds, Albany, NY
5/10 10/10	"Transition from Pediatric to Adult CF Care," Cystic Fibrosis Learning Consortium, New York, NY "Diagnosing Adults with Mild or Atypical CF," 2010 North American Cystic Fibrosis Meetings,
10/10	Baltimore MD
10/11	"Clinical Trial Design for MRSA in Cystic Fibrosis," 2011 North American Cystic Fibrosis Meetings
	Anaheim, CA
10/11	"Results of Cohort 1 of the Phase II VX809-102 Trial," 2011 North American Cystic Fibrosis Meetings,
	2011 North American CF Meetings, Anaheim, CA
4/12	"Correlating Genotype and Phenotype in Cystic Fibrosis," University of Florida Pediatric Pulmonary
F /10	Symposium, University of Florida, Gainesville, FL
5/12	"The Future of Genotype Specific Therapy in Cystic Fibrosis," Kit Taylor Memorial Lecture, University of Rochester Medical Center, Rochester, NY
5/12	"Recognizing and Diagnosing Late Manifestations of Cystic Fibrosis," 2012 American Thoracic Society
	(ATS) Meetings, San Francisco, CA
7/12	Keynote Speaker: "CFTR Modulation Therapy: Who will Benefit?" Cystic Fibrosis Research Institute
10/10	Annual Meetings, San Francisco, CA
10/12	"The Investigational CFTR Corrector, VX-809 (Lumacaftor) Co-Administered with the Oral Potentiator
	Ivacaftor Improved CFTR and Lung Function in F508DEL Homozygous Patients: Phase II Study Results." Michael Boyle, Scott Bell, Michael Konstan, Susanna McColley, Lisa Kang, Naimish Patel,
	and David Rodman for the VX09-809-102 Study Group. Pediatric Pulmonology 47;S35:260, 2012,
	Presented by Michael Boyle at North American CF Meetings 2012
3/13	"The New Era of Cystic Fibrosis Therapeutics." Albert Einstein/Beth Israel Hospital Medicine Grand
-	Rounds: The Ann and Mort David Pulmonary Lecture. New York, NY.
4/13	University of Virginia Cystic Fibrosis Education Day: "The New Cystic Fibrosis Therapies – Who will
	benefit?" Charlottesville, VA.
12/13	"New Advances in Cystic Fibrosis Therapeutics." Drexel University Pulmonary Grand Rounds.
	Philadelphia, PA.

- 2/14 "The Future of Cystic Fibrosis: Adult Care and Genotype Specific Therapy", University of Arizona Winter Respiratory Lecture. Tucson, Arizona.
- 10/14 "Climbing the Mountain: The Journey to Delivering Transformational Cystic Fibrosis Therapeutics". Opening Plenary Address, North American Cystic Fibrosis Conference, Atlanta, Georgia. Plenary available (starts at minute 36): https://www.nacfconference.org/art/2014_Plenary1.wmy
- 4/15 "The Future of Cystic Fibrosis: Genotype Specific Therapy", VCU CF Family Education Day, Richmond, VA.
- 4/15 "The Journey to Delivering Transformational Cystic Fibrosis Therapeutics", All Children's Hospital, Tampa, FL.
- 5/15 "Managing Cystic Fibrosis to Prevent Lung Function Decline", ATS 2015 Post-graduate Course, Denver Colorado.



3.	Your Name: MICHAEL P. BOYCE, M.D. Your Title: PRAFESSAR OF MEDICANE, JOHNS HOPKINS VICE PRESIDENT THERAPENTICS DEVELOPMENT, CLORE FIBRON FO The Entity(ies) You are Representing: CYSTIC FIBROSIS FOUNDATION
•.	Are you testifying on behalf of the Federal, or a State or localYesNogovernment entity?X
5.	Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2013. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.
	None

Signature:

F